IN2015DN02349A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02349A IN2015DN02349A IN2349DEN2015A IN2015DN02349A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A IN 2349DEN2015 A IN2349DEN2015 A IN 2349DEN2015A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A
- Authority
- IN
- India
- Prior art keywords
- conjugates
- specific
- peptide
- binding protein
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261717743P | 2012-10-24 | 2012-10-24 | |
US201261717710P | 2012-10-24 | 2012-10-24 | |
US201361811285P | 2013-04-12 | 2013-04-12 | |
PCT/GB2013/051593 WO2013190292A2 (fr) | 2012-06-19 | 2013-06-19 | Nouveau procédé de préparation de conjugués d'anticorps et nouveaux conjugués d'anticorps |
PCT/GB2013/052661 WO2014064423A1 (fr) | 2012-10-24 | 2013-10-11 | Conjugués médicament-protéine |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN02349A true IN2015DN02349A (fr) | 2015-08-28 |
Family
ID=50544085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2349DEN2015 IN2015DN02349A (fr) | 2012-10-24 | 2013-10-11 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20150290342A1 (fr) |
EP (2) | EP2911700B1 (fr) |
JP (1) | JP6328648B2 (fr) |
KR (1) | KR102209395B1 (fr) |
CN (1) | CN104870021B (fr) |
AU (1) | AU2013336409B2 (fr) |
BR (1) | BR112015008376A2 (fr) |
CA (1) | CA2884299A1 (fr) |
DK (1) | DK2911700T5 (fr) |
ES (1) | ES2623209T3 (fr) |
HK (1) | HK1208187A1 (fr) |
IL (1) | IL237672B (fr) |
IN (1) | IN2015DN02349A (fr) |
MX (1) | MX2015005122A (fr) |
MY (1) | MY169147A (fr) |
RU (1) | RU2015119561A (fr) |
SG (1) | SG11201501618WA (fr) |
WO (1) | WO2014064423A1 (fr) |
ZA (1) | ZA201501642B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2913732A1 (fr) * | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions et procedes permettant de conjuguer des anticorps activables |
PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
WO2015179734A1 (fr) * | 2014-05-23 | 2015-11-26 | Novartis Ag | Procédés pour la fabrication ce conjugués à partir de protéines contenant des liaisons disulfures |
KR102451080B1 (ko) * | 2014-06-12 | 2022-10-06 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 효소적 방법을 통한 균일한 항체 약물 접합체 |
EP3218009B1 (fr) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Procédé pour la conjugaison d'un peptide ou d'une protéine avec un réactif comprenant un groupe partant comportant une partie de peg |
WO2016063006A1 (fr) * | 2014-10-24 | 2016-04-28 | Polytherics Limited | Conjugués et réactifs de conjugaison |
GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
TWI660741B (zh) | 2015-11-03 | 2019-06-01 | 財團法人工業技術研究院 | 抗體藥物複合物及其製造方法 |
MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
WO2017161206A1 (fr) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation |
BR112018069273A2 (pt) | 2016-03-25 | 2019-01-22 | Seattle Genetics Inc | métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco |
EP3442595A1 (fr) | 2016-04-14 | 2019-02-20 | Polytherics Limited | Conjugués et réactifs de conjugaison comprenant un lieur qui comprend au moins deux motifs (-ch2-ch2-o-) dans un cycle |
GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
CN109311996B (zh) * | 2016-06-06 | 2023-11-28 | 阿布泽纳(英国)有限公司 | 抗体、其用途及其缀合物 |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
MX2019010769A (es) | 2017-03-24 | 2019-12-11 | Seattle Genetics Inc | Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos. |
GB201820864D0 (en) * | 2018-12-20 | 2019-02-06 | J A Kemp | Antibody-drug conjugates |
KR20230002672A (ko) * | 2020-04-15 | 2023-01-05 | 선전 엔듀어링 바이오테크 리미티드 | 항체-약물 접합체 |
AU2022237459A1 (en) * | 2021-03-19 | 2023-09-21 | Shenzhen Enduring Biotech, Ltd. | Pegylated t cell engager with dual specificities to cd3 and cd19 |
WO2023141855A1 (fr) * | 2022-01-27 | 2023-08-03 | Glyco-Therapy Biotechnology Co., Ltd. | Conjugués protéiques à charges utiles multiples et leurs procédés de fabrication |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
EA016577B1 (ru) * | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
PT2211904T (pt) * | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
ES2647927T3 (es) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
BRPI0911442A2 (pt) * | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
EP2403538B1 (fr) | 2009-03-04 | 2017-10-04 | Polytherics Limited | Protéines et peptides conjugués |
WO2010120561A1 (fr) * | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation |
UY32913A (es) * | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
EP2841958A1 (fr) * | 2012-04-25 | 2015-03-04 | Koninklijke Philips N.V. | Système et procédé de localisation d'une bobine de gradient |
KR20150023027A (ko) * | 2012-06-19 | 2015-03-04 | 폴리테릭스 리미티드 | 항체 접합체의 제조를 위한 신규한 공정 및 신규한 항체 접합체 |
-
2013
- 2013-10-11 MY MYPI2015701285A patent/MY169147A/en unknown
- 2013-10-11 RU RU2015119561A patent/RU2015119561A/ru unknown
- 2013-10-11 BR BR112015008376A patent/BR112015008376A2/pt not_active Application Discontinuation
- 2013-10-11 MX MX2015005122A patent/MX2015005122A/es unknown
- 2013-10-11 EP EP13786530.9A patent/EP2911700B1/fr active Active
- 2013-10-11 ES ES13786530.9T patent/ES2623209T3/es active Active
- 2013-10-11 KR KR1020157011427A patent/KR102209395B1/ko active IP Right Grant
- 2013-10-11 CA CA2884299A patent/CA2884299A1/fr not_active Abandoned
- 2013-10-11 CN CN201380055880.6A patent/CN104870021B/zh active Active
- 2013-10-11 US US14/437,537 patent/US20150290342A1/en not_active Abandoned
- 2013-10-11 JP JP2015538560A patent/JP6328648B2/ja active Active
- 2013-10-11 IN IN2349DEN2015 patent/IN2015DN02349A/en unknown
- 2013-10-11 WO PCT/GB2013/052661 patent/WO2014064423A1/fr active Application Filing
- 2013-10-11 EP EP16203350.0A patent/EP3159013A1/fr not_active Withdrawn
- 2013-10-11 SG SG11201501618WA patent/SG11201501618WA/en unknown
- 2013-10-11 DK DK13786530.9T patent/DK2911700T5/en active
- 2013-10-11 AU AU2013336409A patent/AU2013336409B2/en active Active
-
2015
- 2015-03-10 ZA ZA2015/01642A patent/ZA201501642B/en unknown
- 2015-03-11 IL IL237672A patent/IL237672B/en active IP Right Grant
- 2015-09-11 HK HK15108932.7A patent/HK1208187A1/xx unknown
-
2021
- 2021-09-17 US US17/477,565 patent/US20220062436A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2013336409B2 (en) | 2017-08-03 |
KR102209395B1 (ko) | 2021-01-28 |
DK2911700T3 (en) | 2017-05-15 |
SG11201501618WA (en) | 2015-04-29 |
BR112015008376A2 (pt) | 2017-09-26 |
HK1208187A1 (en) | 2016-02-26 |
JP6328648B2 (ja) | 2018-05-23 |
RU2015119561A (ru) | 2016-12-20 |
AU2013336409A1 (en) | 2015-04-02 |
EP3159013A1 (fr) | 2017-04-26 |
KR20150103656A (ko) | 2015-09-11 |
IL237672A0 (en) | 2015-04-30 |
ES2623209T3 (es) | 2017-07-10 |
WO2014064423A1 (fr) | 2014-05-01 |
IL237672B (en) | 2018-02-28 |
MY169147A (en) | 2019-02-18 |
CN104870021A (zh) | 2015-08-26 |
JP2015533847A (ja) | 2015-11-26 |
MX2015005122A (es) | 2015-10-29 |
EP2911700B1 (fr) | 2017-02-08 |
US20150290342A1 (en) | 2015-10-15 |
ZA201501642B (en) | 2016-01-27 |
US20220062436A1 (en) | 2022-03-03 |
CN104870021B (zh) | 2018-03-13 |
EP2911700A1 (fr) | 2015-09-02 |
CA2884299A1 (fr) | 2014-05-01 |
DK2911700T5 (en) | 2017-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN02349A (fr) | ||
CY1122490T1 (el) | Αντισωματα κατα του ανθρωπινου cd38 | |
MX2015005124A (es) | Conjugados de farmaco-proteina. | |
MY168297A (en) | Cytotoxic Peptides and Antibody Drug Conjugates Thereof | |
PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
TN2013000245A1 (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
TN2015000396A1 (en) | Antibody drug conjugates | |
NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
NZ630542A (en) | Methods of treating a tauopathy | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
TN2011000232A1 (en) | Antitumor combinations containing antibodies recognizing specifically cd38 melphalan | |
MX340062B (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida. | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
MX2013002718A (es) | Composiciones de anticuerpo anti-vegfr-3. | |
MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
TN2011000153A1 (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide |